United Therapeutics Corporation UTHR shares plunged around 9% on Monday after the company announced that regulatory issues will delay the planned U.S. launch of RemoSynch - an implantable pump for ...
United Therapeutics Corporation’s UTHR revealed though an 8-K filing that it was informed (Mar 15, 2016) by its partner Medtronic plc MDT that the FDA had issued a response letter to Medtronic’s ...
It took Novartis' Sandoz years to reach the market with a generic to United Therapeutics’ pulmonary arterial hypertension drug Remodulin, but last month, the company managed to do just that. Now, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results